Jennifer Malloy, PA
Medical · Timonium, MDNPI 1265983563
Payments from drug & device makers
Across 241 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$644
- Sanofi-aventis U.S. LLC$508
- AbbVie$359
- Lilly USA, LLC$325
- Amgen$319
- Novo Nordisk$305
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,85799%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 19 | $644 |
| Sanofi-aventis U.S. LLC | 17 | $508 |
| AbbVie | 17 | $359 |
| Lilly USA, LLC | 13 | $325 |
| Amgen(2 entities) | 15 | $319 |
| Novo Nordisk | 17 | $305 |
| Dexcom, Inc. | 7 | $298 |
| Tandem Diabetes Care, Inc. | 7 | $274 |
| Insulet Corporation | 8 | $273 |
| Radius Health, Inc. | 11 | $264 |
| AstraZeneca(2 entities) | 12 | $220 |
| Abbott | 7 | $155 |
| Xeris Pharmaceuticals, Inc. | 8 | $154 |
| Cequr Corporation | 3 | $153 |
| Amneal Pharmaceuticals LLC | 7 | $153 |
| Boehringer Ingelheim | 8 | $141 |
| BETA Bionics, Inc. | 3 | $130 |
| Novartis | 6 | $124 |
| Medtronic | 6 | $107 |
| Antares Pharma, Inc. | 5 | $96 |
| Recordati_rare_diseases_inc. | 5 | $95 |
| Neurocrine Biosciences, Inc. | 3 | $80 |
| Almatica Pharma LLC | 3 | $70 |
| Lifescan, Inc. | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $59 |
| Kyowa Kirin, Inc. | 3 | $58 |
| Bayer | 3 | $55 |
| IBSA Pharma Inc. | 3 | $54 |
| Mannkind Corporation | 3 | $45 |
| Zealand Pharma US, Inc. | 2 | $42 |
| Embecta Corp. | 1 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| BD | 1 | $29 |
| Tolmar, Inc. | 2 | $27 |
| Pfizer | 1 | $26 |
| Soleno Therapeutics, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$231
- Omnipod$125
- t:slim X2 Insulin Pump with Control-IQ$123
- DEXCOM G7 GSS (161)$118
- MOUNJARO$101
How this compares
$5,892 in reported general payments places this provider in the 85th percentile of 543 medical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 264 | $488,667 |
| TrulicityDulaglutide | 111 | $177,757 |
| JardianceEmpagliflozin | 97 | $123,702 |
| MounjaroTirzepatide | 68 | $116,648 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $89,054 |
| RybelsusSemaglutide | 37 | $79,518 |
| FarxigaDapagliflozin Propanediol | 60 | $71,766 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $71,755 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 74 | $46,955 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $43,934 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $37,374 |
| JanuviaSitagliptin Phosphate | 27 | $33,619 |
| Humalog Kwikpen U-100Insulin Lispro | 42 | $25,508 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 122 | $24,789 |
| Novolog FlexpenInsulin Aspart | 52 | $21,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $305 | $591,932324 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $325 | $306,460203 claims |
| Boehringer IngelheimJardiance | $141 | $123,70297 claims |
| AstraZenecaFarxiga | $220 | $71,76660 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $508 | $39,38145 claims |
| AbbVieSynthroid | $359 | $6,73867 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $153 | $1,461129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 543 medical providers in Maryland.
Other medical in Timonium
- Rivkah HorowitzTimonium$7K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.